Previous studies identified partial inhibitors and allosteric modulators of 5-hydroxytryptamine ([5-amino-3-(3,4-dichlorophenyl ). We report here the identification of three novel allosteric modulators of the dopamine transporter [N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine [SoRI-20040], N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine [SoRI-20041] 3 H]1-methyl-4-phenylpyridinium ion from rat caudate synaptosomes in a dose-dependent manner. Viewed collectively, we report several compounds that allosterically modulate hDAT binding and function, and we identify novel partial inhibitors of amphetamine-induced dopamine release.
with EC 50 values ranging from ϳ1.4 to 3 M and E max values decreasing as the [ 125 I]RTI-55 concentrations increased. All three compounds decreased the [ 125 I]RTI-55 B max value and increased the apparent K d value in a manner well described by a sigmoid dose-response curve. In dissociation rate experiments, SoRI-20040 (10 M) and SoRI-20041 (10 M), but not SoRI-2827 (10 M), slowed the dissociation of [ 125 I]RTI-55 from hDAT by ϳ30%. Using rat brain synaptosomes, all three agents partially inhibited [ 3 H]dopamine uptake, with EC 50 values ranging from 1.8 to 3.1 M and decreased the V max value in a dose-dependent manner. SoRI-9804 and SoRI-20040 partially inhibited amphetamine-induced dopamine transporter-mediated release of [ 3 H]1-methyl-4-phenylpyridinium ion from rat caudate synaptosomes in a dose-dependent manner. Viewed collectively, we report several compounds that allosterically modulate hDAT binding and function, and we identify novel partial inhibitors of amphetamine-induced dopamine release.
The biogenic amine transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT), are important targets for a wide range of medications used to treat a variety of psychiatric conditions, such as anxiety, depression, and obsessive compulsive disorder (Gorman and Kent, 1999; Zohar and Westenberg, 2000) . Drugs that interact with transporters generally interact with these proteins in two distinct ways. Reuptake inhibitors bind to transporter proteins but are not transported. These drugs elevate extracellular concentrations of transmitter by blocking transporter-mediated uptake of transmitters from the synapse. Substrate-type releasers bind to transporter proteins and are subsequently transported into the cytoplasm of nerve terminals, releasing neurotransmitter via a process of carrier-mediated exchange (Rudnick and Clark, 1993; Rothman and Baumann, 2006) .
There is growing interest in the possible therapeutic po-tential of allosteric modulators (Christopoulos and Kenakin, 2002; Schwartz and Holst, 2007) , including the identification of allosteric modulators of the biogenic amine transporters (BATs) (Sanchez, 2006) . Early evidence of allosteric interactions at the biogenic amine transporters included our finding that pretreatment of guinea pig membranes with paroxetine increased the dissociation rate of [ 3 H]cocaine from SERT (Akunne et al., 1992) . Using rat SERT expressed in HEK cells, Sur et al. (1998) presented evidence that imipramine allosterically modulated the ability of citalopram to inhibit [ 3 H]5-hydroxytryptamine transport. Others reported apparent allosteric interactions between 5-hydroxytryptamine and [ 3 H]paroxetine binding to human platelet SERT (Andersson and Marcusson, 1989) and between ␤-estradiol and SERT (Chang and Chang, 1999) . More recently, we reported novel allosteric modulators of both DAT (SoRI-9804) (Rothman et al., 2002) and SERT (SoRI-6238 and TB-1-099) (Nandi et al., 2004; Nightingale et al., 2005) . Moreover, Chen et al. (2005) reported evidence for allosteric modulation of [ 3 H]S-citalopram binding (Chen et al., 2005) .
In 1999, we searched a library of compounds maintained by Southern Research Institute (Birmingham, AL) for compounds that possessed a diphenylmethyl (benzhydryl) group. Using rat brain tissue assays, we screened these compounds for activity in binding assays for DAT, SERT, and NET (unpublished data). This effort identified several possible allosteric modulators of the BATs. We examined in greater detail the interaction of selected agents with the BATs. SoRI-9804 ( Fig. 1) 3 H]DA uptake by rat brain synaptosomes. SoRI-6238, and a subsequent compound that was not part of the SoRI library (TB-1-099), were shown to allosterically modulate SERT (Nandi et al., 2004; Nightingale et al., 2005) . In the present study, we focused on three additional compounds identified as being potential allosteric modulators ( Fig. 1) : SoRI-20040, SoRI-20041, and SoRI-2827 . Initial screens indicated that all three agents were inactive at NET and SERT binding (IC 50 Ͼ 10 M) but inhibited [
125 I]RTI-55 binding to the rat brain DAT in a manner suggestive of allosteric interactions. We report here that these three agents allosterically modulate the human DAT (hDAT) ex- 
Materials and Methods
Animals. Male Sprague-Dawley rats (300 -450 g), used for 3 H neurotransmitter uptake assays, were obtained from Charles River Laboratories, Inc. (Wilmington, MA). The animal housing facilities were fully accredited by the American Association of the Accreditation of Laboratory Animal Care, and all experiments were performed within the guidelines delineated in the Institutional Care and Use Committee of the National Institute on Drug Abuse, Intramural Research Program.
Tissue Preparation. HEK cells expressing hDAT were grown to confluence on plates, using published methods (Nightingale et al., 2005) . The medium was removed, and the plates were stored at Ϫ80°C until the day of the assay. The plates were thawed, and then the cells were scraped off and rinsed with 55.2 mM sodium phosphate buffer, pH 7.4 (BB), and homogenized with a Polytron homogenizer at setting 6 for 10 s. The homogenate was centrifuged twice at 30,000g for 10 min, with resuspensions in BB. The final pellets were resuspended in a final volume of 225 ml/plate with BB.
Transporter Binding Assays. For assays using HEK cells expressing hDAT, experiments were carried out in 12-ϫ 75-mm polystyrene tubes that were prefilled with 100 l of drug, 100 l of radioligand, and 50 l of a blocker or buffer (Rothman et al., 1998) . [ 125 I]RTI-55 was diluted in a protease inhibitor cocktail (BB with 25 g/ml chymostatin, 25 g/ml leupeptin, 1 mM EGTA, and 1 mM EDTA). The drugs and blockers were made up in BB with 1 mg/ml bovine serum albumin at pH 7.4. The experiment was initiated with the addition of 750 l of membranes in BB. Samples were incubated in a final volume of 1 ml, at 0°C for 18 to 24 h (steady state). After incubation, the samples were filtered with a cell harvester (Brandel Inc., Gaithersburg, MD), over Whatman GF/B filters (Whatman, Clifton, NJ) presoaked in wash buffer (ice-cold 10 mM Tris-HCl and 150 mM NaCl, pH 7.4) containing 2% poly(ethyleneimine). Typical total and nonspecific cpms observed for the HEK cell transporter binding assays were 2000 and 75, respectively.
Kinetic Experiments. Kinetic experiments were conducted with minor modifications of published methods (Nandi et al., 2004 Neurotransmitter Uptake Assays. [ 3 H]DA uptake inhibition assays were conducted as described previously (Rothman et al., 2001) . Freshly removed caudate ([ 3 H]DA uptake) was homogenized in 10% ice-cold sucrose with 12 strokes of a hand-held PotterElvehjem homogenizer followed by centrifugation at 1000g for 10 min. The supernatants were saved on ice and used immediately. The assay buffer used was Krebs' phosphate buffer containing 154.4 mM NaCl, 2.9 mM KCl, 1.1 mM CaCl 2 , 0.83 mM MgCl 2 , 5 mM glucose, 1 mg/ml ascorbic acid, and 50 M pargyline. Nonspecific uptake was measured by incubating in the presence of 10 M indatraline. The reactions were stopped after 15 min by filtering with a cell harvester (Brandel Inc.) over Whatman GF/B filters (Whatman) presoaked in wash buffer maintained at 25°C (10 mM Tris-HCl, pH 7.4, and 150 mM NaCl). Retained tritium was measured with a Trilux liquid scintillation counter (PerkinElmer Life and Analytical Sciences, Shelton, CT) after overnight extraction in 0.6 ml of liquid scintillation cocktail (MP Biomedicals, Solon, OH). Typical total and nonspecific cpms observed for the rat brain transporter uptake inhibition assays were 18,000 and 1000, respectively.
[ 3 H]MPP ؉ Release Assays. This assay measures the ability of test agents to release preloaded [ 3 H]MPP ϩ via the DAT using rat striatal synaptosomes. The details of this assay were published previously (Rothman et al., 2003) .
Experimental Design. Inhibition curves were generated by displacing one to three concentrations of [
125 I]RTI-55 by 10 concentrations of drug. Concentrations of [
125 I]RTI-55 greater than 0.01 nM were generated by addition of nonradioactive RTI-55. For binding surface experiments (Rothman, 1986; Rothman et al., 1991) (Rothman et al., 1991) .
Data Analysis and Statistics. Inhibition curve data were expressed as "percentage of inhibition" and fit to the following twoparameter dose-response curve model:
for the best fit estimates of the E max and EC 50 values using either KaleidaGraph version 3.6.4 (Synergy Software, Reading, PA) or MLAB-PC (Nightingale et al., 2005) . Binding surfaces were fit to one-and two-site binding models using MLAB-PC as described previously (Rothman et al., 1991) . Dissociation experiments were fit to one-or two-component dissociation models (Nandi et al., 2004) . Statistical significance among binding models was determined using the F-test, with a threshold of p Ͻ 0.01. Graphs were generated with KaleidaGraph 3.6 software. I͔RTI-55 (0.01 nM) to hDAT proceeded for 2 h at 25°C. At this point (time 0), RTI-55 (1 M) was added to conditions 2 and 4. Ten minutes later, test drugs were added to conditions 3 and 4. For the data analysis, the 100% of control point was time 0 min for conditions 1 and 2 and time 10 min for conditions 3 and 4. Each data point is the mean Ϯ S.D. of three experiments. The data were fit to a one-(conditions 1, 2, and 4) or two-component (condition 3) exponential decay model using KaleidaGraph version 3.6 to calculate the kinetic constants.
Condition
First (Rothman et al., 1998) .
Results
The first series of experiments determined the inhibitory effect of SoRI-20040, SoRI-20041, and SoRI-2827, in 125 I]RTI-55. It is expected that increasing the concentration of a competitive inhibitor would have no effect on the B max value but would increase the apparent K d value linearly according to the equation Fig. 4A , 0.8 and 12.8 M SoRI-20040 significantly reduced the B max value by 17 and 32%, respectively. SoRI-20040 also increased the apparent K d value in a dose-dependent manner that was well described by a sigmoidal dose-response curve, rather than the linear curve expected of a competitive inhibitor. SoRI-20041 (Fig. 5) significantly decreased the B max value at all three test concentrations and also increased the apparent K d value in a dose-dependent manner, which was also well described by a sigmoidal dose-response curve. Similar results were observed for SoRI-2827, except that this compound decreased the B max value only at the 3.2 M concentration (Fig. 6) .
The next series of experiments determined the effect of the SoRI agents on the dissociation kinetics of [ 125 I]RTI-55 binding to hDAT. Table 2 reports the experimental design used for these experiments. In brief, addition of RTI-55 (1 M) initiated the dissociation of [
125 I]RTI-55 binding, after which test drugs were added so that any effect of the test agent could not be due to an effect at the transporter binding site, ]RTI-55 for 2 h at 25°C. At this point, baseline samples were filtered, and then RTI 55 (1 M) was added to samples 2 and 4. Ten minutes later, test drug was added to samples 3 and 4 to generate the following conditions: control (no addition; sample 1), RTI-55 (1 M; sample 2), test drug (10 M; sample 3), and RTI-55 (1 M) ϩ test drug (10 M; sample 4). For the data analysis, the 100% of control point was time 0 min for conditions 1 and 2 and time 10 min for conditions 3 and 4. Samples were then filtered at the indicated times. The data of conditions 2 and 4 were fit to a one-component dissociation model, and the data of condition 3 was fit to a two-component dissociation model (see Tables 2 and 3 because these were prebound with RTI-55. As reported in Fig. 7A and (Rothman and Baumann, 2006) . As reported in Fig. 9 and Table 7 , D-amphetamine produced a dose-dependent release of [ 3 H]MPP ϩ , with an EC 50 value of ϳ6 nM and an E max value of 100%. Cocaine (2.8 M) shifted the D-amphetamine curve to the right (EC 50 ϭ 82 nM) without altering the E max value. SoRI-9804 produced a dose-dependent decrease in the E max value, resulting in an E max value of 73% with the 10 M dose. Similar results were obtained with SoRI-20040 ( Fig. 10; Table 7 ). In these experiments, indatraline (66 nM) shifted the D-amphetamine curve to the right (EC 50 ϭ 116 nM) without altering the E max value. SoRI-20040 produced a dose-dependent decrease in the E max value, resulting in an E max value of 60% with the 10 M dose. At 10 M, SoRI-9804 did not affect 
Discussion
Based on our experience screening hundreds of compounds in biogenic amine transporter binding assays (Prisinzano et al., 2004) , most agents inhibited rat brain DAT binding with slope factors (Hill coefficients) close to 1, a finding strongly suggestive of a binding process governed by simple mass action kinetics. SoRI-9804 was the first compound we came across that inhibited [
125 I]RTI-55 binding to DAT in a qualitatively different manner (Rothman et al., 2002) . As observed in this study with SoRI-20040, SoRI-20041, and SoRI- 
I͔RTI-55 from hDAT
Dissociation experiments were conducted as described in Table 2 Ten-point inhibition curves were generated for each test drug using 5 nM ͓ 3 H͔DA. The data were transformed to percentage of inhibition and fit to the dose-response curve for the best-fit estimates of the EC 50 and E max values, using KaleidaGraph version 3.6.4. All curves were generated from an n ϭ 3. Each value is ϮS.D.
EC 50
E max nM % 2827, SoRI-9804 partially inhibited DAT binding and [ 3 H]DA uptake. We reported previously on other compounds that allosterically modulate SERT (Nandi et al., 2004; Nightingale et al., 2005) .
Early hints of allosteric interactions at the biogenic amine transporters included our finding that pretreatment of guinea pig membranes with paroxetine increased the dissociation rate of [ 3 H]cocaine from SERT (Akunne et al., 1992) . Using rat SERT expressed in HEK cells, Sur et al. (1998) (Andersson and Marcusson, 1989) and between ␤-estradiol and SERT (Chang and Chang, 1999) . More recently, we reported novel allosteric modulators of both DAT (Rothman et al., 2002) and SERT (Nandi et al., 2004) , and Chen et al. (2005) Ten-point cocaine inhibition curves (50 -5052 nM) were generated using 2 nM ͓ 3 H͔DA in the absence and presence of the indicated test agents. The data of several independent experiments were pooled and fit to the two-parameter logistic equation for the best-fit estimate of the IC 50 value (ϮS.D.).
Drug
IC 50 Specific Uptake
Cocaine 278 Ϯ 9 100 (n ϭ 6, 60 data points) Cocaine ϩ SoRI-20040 (12.8 M) 402 Ϯ 30* 43 Ϯ 10 (n ϭ 3, 30 data points) Cocaine ϩ SoRI-20041 (12.8 M) 450 Ϯ 20* 27 Ϯ 4 (n ϭ 3, 30 data points) Cocaine ϩ SoRI-2827 (12.8 M) 582 Ϯ 45* 44 Ϯ 6 (n ϭ 3, 30 data points) Cocaine ϩ indatraline (7 nM) 894 Ϯ 100* 31 Ϯ 7 (n ϭ 3, 30 data points) 62% for SoRI-20040. We observed similar results for the partial inhibition of opioid receptor binding by salvinorin A (Rothman et al., 2007) . These observations suggest that the fractional occupation of the receptor by the radioligand affects the ability of the allosteric drug to displace binding. Second, all three SoRI compounds affected the K d and B max values of [
125 I]RTI-55 binding to hDAT in a manner unlike that of a competitive inhibitor. All three agents decreased the B max and increased the apparent K d value in a dose-dependent manner (Figs. 3-6 ) (mixed inhibition model). The doseresponse curves were well described by a sigmoidal doseresponse curve, rather than the linear curve expected of a competitive inhibitor. The low micromolar EC 50 values for increasing the apparent K d values (Figs. 4 -6 The dissociation experiments provide a third line of evidence indicating that the SoRI-20040 and SoRI20041 allosterically modulate hDAT (Fig. 7) . Dissociation experiments are classically used to detect allosteric effects, specifically comparing the dissociation rate observed when dissociation is initiated by dilution versus the addition of an excess of a competing ligand. However, as described in our previous work (Nandi et al., 2004) , the dilution method does not work in the hDAT binding assay, because reassociation of the radioligand occurs during the dissociation experiment. Thus, we determined the ability of a test agent to alter [
125 I]RTI-55 dissociation initiated by the addition of 1 M RTI-55. The test agents were added 10 min after the RTI-55, ensuring that any effect observed could not be due to interactions at the RTI-55 hDAT binding site ( Table 2 ). As reported in Table  3 , SoRI-20040 and SoRI-20041, but not SoRI-2827 , slowed the dissociation rate, providing clear evidence of an allosteric effect. The addition of the SoRI compounds in the absence of RTI-55 resulted in biphasic dissociation curves, the faster component of which (A1) was similar to that observed with the addition of RTI-55. Because these compounds do not completely inhibit [
125 I]RTI-55 binding, the simplest explanation of the biphasic dissociation curves is that these compounds initiated a more rapid dissociation (K Ϫ1 ) followed by a much slower (K Ϫ2 ) dissociation and a reassociation of nM at all three concentrations tested (0.8, 3.2, and 12.8 M) . Only one compound (SoRI-20041) increased the K M value in a dose-dependent manner. In this case, the data were well described by a sigmoidal dose-response curve, with an EC 50 value of 1.6 Ϯ 0.02 M and an E max value of 73 Ϯ 0.2% (data not shown). All three SoRI compounds decreased Eight-point dose-response curves were generated using 5 nM [
3 H]MPP ϩ in the absence and presence of the indicated test agents. The data of three independent experiments were pooled (24 data points) and fit to the dose-response equation for the best-fit estimate of the EC 50 and E max values (ϮS.D.) (see Table 7 ).
the V max value of [ 3 H]DA uptake. SoRI-20040 and SoRI-20041 decreased the V max value in a dose-dependent manner (Fig. 8) ϩ via DAT to the right, without altering the E max value. In contrast, 10 M SoRI-9804 (Fig. 9) and 10 M SoRI-20040 (Fig. 10) In summary, various studies over the years hint of an allosteric binding site associated with the biogenic amine transporters. The data presented here indicate that SoRI-20040 and SoRI-20041 allosterically modulate DAT and that SoRI-2827 interacts with DAT in a manner not consistent with that of simple competitive inhibitor. Our study therefore presents strong evidence for such an allosteric modulatory site and identifies novel partial inhibitors of DAT-mediated dopamine release. Such partial inhibitors, by reducing the effects of amphetamine, might be of use in the treatment of methamphetamine dependence.
